Brentuximab vedotin for advanced Hodgkin lymphoma in the ECHELON-1 study

An update on the COBRA trial: PET-response adapted treatment with brentuximab vedotin for HLПодробнее

5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphomaПодробнее

Phase III ECHELON-1 study: Updated results of brentuximab vedotin + chemotherapy for untreated cHLПодробнее

Five year update of ECHELON-1 for classical Hodgkin lymphomaПодробнее

Initial Therapy of Advanced Stage Hodgkin Lymphoma: When to Use ABVD, A(BV)VD, and BEACOPPПодробнее

Echelon-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 cla...Подробнее

Research Builds On Positive ECHELON-1 Study in Hodgkin LymphomaПодробнее

Overview of ECHELON-1 Study for Hodgkin LymphomaПодробнее

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphomaПодробнее

Results of ECHELON-1 study for Hodgkin LymphomaПодробнее

Debate: Best upfront approach for Advanced Stage Hodgkin Lymphoma? - A (brentuximab vedotin) VDПодробнее

A New Frontline Treatment Option for Hodgekin LymphomaПодробнее

Frontline BVAVD in Classical Hodgkin LymphomaПодробнее

Improving Targeted Therapies for Patients with Previously Untreated Advanced Classic Hodgkin LymphomПодробнее

ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVDПодробнее

A Study of Brentuximab Vedotin Plus AVD in Hodgkin LymphomaПодробнее

Dr. Hutchings on the Aim of the ECHELON-1 Study in Hodgkin LymphomaПодробнее

Patient Selection Based on the ECHELON-1 Study in cHLПодробнее

Debate: Brentuximab vedotin as upfront therapy for advanced Hodgkin lymphoma? - YesПодробнее

Martin Hutchings, EHA 2018 – ECHELON-1 trial and chemotherapy regimens in Hodgkin’s lymphomaПодробнее